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An international exposé of flawed regulations for medical implants prompted Canada’s health 
minister to announce sweeping changes to the regulation of medical devices.1 Yet an important 
subset of medical devices remains outside the purview of this regulatory overhaul: laboratory-
developed tests. These devices are diagnostic tests produced by a company in its own clinical 
laboratories and marketed as commercial services to health care providers who send samples to 
those laboratories for analysis “in house.” Some laboratory-developed tests may also be 
developed by public clinical laboratories and offered to local clients. The recent expansion of the 
molecular diagnostics industry has revealed weaknesses in the regulatory system for all laboratory 
developed tests. Such tests are not subject to Canada’s statutory regulation of medical devices for 
safety and efficacy, but they are widely used in Canada’s health care system. Absent regulation as 
medical devices, the only controls on test performance are laboratory regulation and 
accreditation, which are heterogeneous and sometimes flawed and do not necessarily include 
assessment of test validity, safety and efficacy. Regulators in Australia, the United States and 
Europe have made efforts to close this “gaping regulatory loophole,”2 but Health Canada has 
not indicated that it plans to do the same. In the interests of the nation’s health, it should.  
Molecular diagnostics increasingly play a pivotal role in control of infectious disease, diagnosis of 
hereditary diseases and aspects of oncology. The global molecular diagnostics market was 
estimated to be worth US$7.3 billion in 2017.3 In Canada, many molecular diagnostics are 
covered by provincial health plans: for example, Harmony and Panorama, noninvasive 
prenatal tests that screen for common fetal trisomies, are covered for high-risk pregnancies in 
Ontario, British Columbia and the Yukon. Oncotype Dx — which offers women with early-
stage invasive breast cancer information about their likely response to chemotherapy and the 
chance of recurring cancer — is reimbursed in BC, Alberta, Saskatchewan, Ontario, Quebec and 
Newfoundland. But these three tests were neither evaluated nor approved by Health Canada.  
 3 
 
Diagnostics developed as “test kits” and sold to laboratories, hospitals and clinics are considered 
to be in vitro diagnostics devices under Medical Devices Regulation in accordance with the 
federal Food and Drugs Act. They are subject to premarket review by Health Canada to evaluate 
evidence of their safety and efficacy. However, manufacturers can avoid this regulatory approval 
process by using the laboratory-developed test loophole. In the past, such tests were developed 
in specialized hospital laboratories; they were not regulated as medical devices and were 
distributed to patients as a health service. But growing commercial interest in molecular 
diagnostics calls this approach into question. Moreover, this regulatory loophole establishes a far-
from-level playing field for test manufacturers, as some widely used tests that have been 
reviewed and approved by Health Canada, such as Prosigna’s NanoString and 
Myriad’s EndoPredict prognostic tests for early-stage breast cancer, compete on the Canadian 
market with tests that have bypassed such review, like Oncotype Dx.  
The current laboratory regulatory system in Canada involves a mixture of public and private 
entities and operates with oversight from provincial governments, nongovernmental 
organizations and professional societies.4,5 Laboratory regulations are aimed at the laboratories 
themselves — addressing laboratory environment, hiring of personnel, laboratory operation, 
accreditation and quality control — but no entity is formally responsible across Canada for 
independently evaluating the development, validity or adverse events of tests delivered by 
laboratories, unless they are marketed as test kits and reviewed by Health Canada (see Appendix 
1, available at www.cmaj.ca/lookup/ suppl/doi:10.1503/cmaj.190550/-/DC1).  
Although the highest laboratory accreditation standards are sometimes mandated,6 most 
provinces and territories rely on voluntary standards that are unevenly applied, with little auditing 
and systematic testing to ensure quality (www.the globeandmail.com/life/health -and-
fitness/what-we-should-learn -from-our-pathology-problems/ article1357271/). This lack 
of proper regulation, controls and quality management “has potentially jeopardized the delivery 
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of quality, safe, timely and appropriate care.”5 Indeed, several high-profile cases of diagnostic 
error in Canadian laboratories have resulted in patient harm7 
(www.cbc.ca/news/canada/motherisk-hair -testing-families-1.4360577).  
Although some laboratory-developed tests have undergone careful review, with findings 
published in scientific journals or endorsed by clinical practice guidelines, others have not. 
Moreover, published evidence often excludes elements essential to the validation of such tests.8 
And there is no test registry. No one, including Health Canada, is keeping track.  
Outside Canada, poor test quality and diagnostic error have drawn attention,9 prompting several 
jurisdictions to address the regulatory weaknesses that contribute to these problems (Appendix 
2, available at www.cmaj.ca/lookup/ suppl/doi:10.1503/cmaj.190550/-/DC1). Australia 
developed a light-touch approach starting in 2010, subjecting only the highest-risk laboratory-
developed tests to external evaluation and tracking in a public registry.10 For class I–III tests 
(lower risk), the system relies on standards for accreditation in compliance with the National 
Association of Testing Authorities, without registration in a public database.  
The US began trying to regulate these tests more than 25 years ago; the US Food and Drug 
Administration (FDA) has exercised enforcement discretion in managing the industry, issuing 
warning and cease-and-desist letters in the face of particularly egregious behaviour, and proposed 
more comprehensive policy reform. In 2010, the FDA began considering a policy change so that 
all such tests would be regulated in the same manner as traditionally distributed in vitro 
diagnostics devices. In 2014, the FDA issued draft guidance to propose clear oversight of 
laboratory-developed tests, but this was withdrawn and replaced with a discussion paper before 
the 2016 presidential election. Most recently, a bipartisan bill has been drafted proposing a 
regulatory framework for all in vitro diagnostics,11 yet its fate is currently unclear.  
A new European Union (EU) regulation on in vitro diagnostics — passed in 2017 and due to be 
fully implemented by 2022 — will subject laboratory-developed tests manufactured on 
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an “industrial scale” to regulatory review. This approach targets commercial laboratories while 
permitting a “health institution exemption” with reduced but still substantial oversight for those 
tests that continue to be used within individual hospital laboratories. Under the new directive, 
the proportion of tests required to be submitted for approval will likely increase from 10% to 
90%.  
In April 2018, the Standards Council of Canada introduced a voluntary standard, in collaboration 
with the Medical Devices Bureau of Health Canada and partners from the clinical 
laboratory industry, Siemens and Roche, for laboratories developing tests. The standard 
acknowledges that “while many laboratories can perform validation studies of these tests, there is 
no standard by which to assess their performance, quality, and reliability.”12 It is similar to the 
Australian regulation, even referencing the Therapeutic Goods Administration when defining 
laboratory-developed tests. Yet Canada seems to be addressing the issue with a lighter touch 
than Australia by failing to regulate even high-risk tests or to track laboratory-developed tests in 
a public registry. The standard is merely a high-level document for laboratories to 
understand how they can voluntarily validate their tests, with much room for interpretation. It is 
an inadequate solution.  
After the exposé on regulation of medical devices, which revealed how a flawed and secretive 
regulatory system caused debilitating injury and death, Canada responded with efforts 
to strengthen the regulatory process for premarket approval of medical devices, enhance 
postmarket surveillance and make the system more transparent. Before this, Canada 
also announced leading regulatory reform on transparency with new requirements for public 
dissemination of clinical data supporting approval of drugs and devices, including regulated 
in vitro diagnostics. In February 2019, Canada’s Medical Devices Regulations were amended, 
giving Health Canada authority to publish “summaries and detailed information of all 
clinical studies and investigational testing that provided evidence of safety and effectiveness” for 
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class III and IV medical devices submitted to them for approval, starting in 2021.13 This 
international leadership in data transparency contrasts starkly with Health Canada’s inadequate 
regulation of laboratory-developed tests. Canada has an opportunity to draw from and build 
on regulatory advances in other countries, particularly the EU, to ensure the safety and 
effectiveness of these diagnostic products. The time to act is now.  
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